198 related articles for article (PubMed ID: 25591934)
1. Role of osteopontin in the regulation of human bladder cancer proliferation and migration in T24 cells.
Xu ST; Guo C; Ding X; Fan WJ; Zhang FH; Xu WL; Ma YC
Mol Med Rep; 2015 May; 11(5):3701-7. PubMed ID: 25591934
[TBL] [Abstract][Full Text] [Related]
2. Targeting MACC1 by RNA interference inhibits proliferation and invasion of bladder urothelial carcinoma in T24 cells.
Xu ST; Ding X; Ni QF; Jin SJ
Int J Clin Exp Pathol; 2015; 8(7):7937-44. PubMed ID: 26339359
[TBL] [Abstract][Full Text] [Related]
3. Effect of siRNA targeting EZH2 on cell viability and apoptosis of bladder cancer T24 cells.
Wang HF; Yang H; Hu LB; Lei YH; Qin Y; Li J; Bi CW; Wang JS; Huo Q
Genet Mol Res; 2014 Nov; 13(4):9939-50. PubMed ID: 25501205
[TBL] [Abstract][Full Text] [Related]
4. Effects of osteopontin downregulation on the growth of prostate cancer PC-3 cells.
Zheng J; Hou ZB; Jiao NL
Mol Med Rep; 2011; 4(6):1225-31. PubMed ID: 21842122
[TBL] [Abstract][Full Text] [Related]
5. [Effect of short-hairpin RNA expression vector-mediated osteopontin RNA interference on proliferation and invasion of prostate cancer PC-3 cells].
Liu H; Chen AM; Guo FJ; Liao H; Hu WH; Xie J
Chin J Cancer; 2010 Jan; 29(1):43-51. PubMed ID: 20038310
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of osteopontin expression by RNA interference affects cell proliferation and chemotherapy sensitivity of breast cancer MDA-MB-231 cells.
Yang L; Wei L; Zhao W; Wang X; Zheng G; Zheng M; Song X; Zuo W
Mol Med Rep; 2012 Feb; 5(2):373-6. PubMed ID: 22143930
[TBL] [Abstract][Full Text] [Related]
7. The potential of osteopontin as a therapeutic target for human colorectal cancer.
Likui W; Hong W; Shuwen Z; Yuangang Y; Yan W
J Gastrointest Surg; 2011 Apr; 15(4):652-9. PubMed ID: 21318445
[TBL] [Abstract][Full Text] [Related]
8. A small interfering RNA targeting osteopontin as gastric cancer therapeutics.
Gong M; Lu Z; Fang G; Bi J; Xue X
Cancer Lett; 2008 Dec; 272(1):148-59. PubMed ID: 18694621
[TBL] [Abstract][Full Text] [Related]
9. Osteopontin accelerates the development and metastasis of bladder cancer via activating JAK1/STAT1 pathway.
Zhang N; Li F; Gao J; Zhang S; Wang Q
Genes Genomics; 2020 Apr; 42(4):467-475. PubMed ID: 32088853
[TBL] [Abstract][Full Text] [Related]
10. A short-hairpin RNA targeting osteopontin downregulates MMP-2 and MMP-9 expressions in prostate cancer PC-3 cells.
Liu H; Chen A; Guo F; Yuan L
Cancer Lett; 2010 Sep; 295(1):27-37. PubMed ID: 20207476
[TBL] [Abstract][Full Text] [Related]
11. RNA interference-mediated vascular endothelial growth factor-C reduction suppresses malignant progression and enhances mitomycin C sensitivity of bladder cancer T24 cells.
Zhang HH; Qi F; Shi YR; Miao JG; Zhou M; He W; Chen MF; Li Y; Zu XB; Qi L
Cancer Biother Radiopharm; 2012 Jun; 27(5):291-8. PubMed ID: 21902544
[TBL] [Abstract][Full Text] [Related]
12. Inducing cell proliferation inhibition, apoptosis, and motility reduction by silencing long noncoding ribonucleic acid metastasis-associated lung adenocarcinoma transcript 1 in urothelial carcinoma of the bladder.
Han Y; Liu Y; Nie L; Gui Y; Cai Z
Urology; 2013 Jan; 81(1):209.e1-7. PubMed ID: 23153939
[TBL] [Abstract][Full Text] [Related]
13. Osteopontin regulates growth and migration of human nasopharyngeal cancer cells.
Yang G; Zhang Y; Wu J; Xiong J; Deng H; Wang J; Yang C; Zhu Z
Mol Med Rep; 2011; 4(6):1169-73. PubMed ID: 21785824
[TBL] [Abstract][Full Text] [Related]
14. Expression of Med19 in bladder cancer tissues and its role on bladder cancer cell growth.
Zhang H; Jiang H; Wang W; Gong J; Zhang L; Chen Z; Ding Q
Urol Oncol; 2012; 30(6):920-7. PubMed ID: 21478038
[TBL] [Abstract][Full Text] [Related]
15. Lentiviral-mediated siRNA targeted against osteopontin suppresses the growth and metastasis of gastric cancer cells.
Wang ZM; Cui YH; Li W; Chen SY; Liu TS
Oncol Rep; 2011 Apr; 25(4):997-1003. PubMed ID: 21286666
[TBL] [Abstract][Full Text] [Related]
16. Silencing of osteopontin promotes the radiosensitivity of breast cancer cells by reducing the expression of hypoxia inducible factor 1 and vascular endothelial growth factor.
Yang L; Zhao W; Zuo WS; Wei L; Song XR; Wang XW; Zheng G; Zheng MZ
Chin Med J (Engl); 2012 Jan; 125(2):293-9. PubMed ID: 22340562
[TBL] [Abstract][Full Text] [Related]
17. Loss of RUNX3 increases osteopontin expression and promotes cell migration in gastric cancer.
Cheng HC; Liu YP; Shan YS; Huang CY; Lin FC; Lin LC; Lee L; Tsai CH; Hsiao M; Lu PJ
Carcinogenesis; 2013 Nov; 34(11):2452-9. PubMed ID: 23774402
[TBL] [Abstract][Full Text] [Related]
18. [Knocking down osteopontin expression by specific siRNA reduces the in vitro invasiveness of human hepatocellular carcinoma cells].
Zhu XQ; Ye QH; Lei KF; Chen J; Qin LX
Zhonghua Zhong Liu Za Zhi; 2006 Jun; 28(6):404-7. PubMed ID: 17152482
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of phospholipase C-epsilon by short-hairpin RNA-mediated gene silencing induces apoptosis in human bladder cancer cell lines.
Zhang Y; Yan L; Zhao Y; Ou L; Wu X; Luo C
Cancer Biother Radiopharm; 2013 Apr; 28(3):233-9. PubMed ID: 23484808
[TBL] [Abstract][Full Text] [Related]
20. Expression and Functions of Formyl Peptide Receptor 1 in Drug-Resistant Bladder Cancer.
Jiang X; Lei T; Zhang M
Technol Cancer Res Treat; 2018 Jan; 17():1533034618769413. PubMed ID: 29665744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
